Jan Moreb, MD
Hematology · Winston Salem, NCNPI 1295774164
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $2,925 of the $4,542 with a category attached, or 64.4%. 19 manufacturers reported payments, led by Karyopharm Therapeutics Inc. at 49.7% of the total. Reporting peaked in 2021 at $2,289 and has fallen 84.6% since, to $354 in 2025. That places this record below the midpoint for hematology clinicians in NC, where the typical reported total is $12,876.
Across 38 payments — averaging $119.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Karyopharm Therapeutics Inc.$2K
- AbbVie$698
- Sanofi$349
- Johnson & Johnson$260
- Pfizer$172
- E.r. Squibb & Sons, L.L.C.$170
- plus $635 from 13 others
Across 83 payments — averaging $1301.14 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi US Services Inc.$65K
- Takeda Pharmaceuticals U.S.A., Inc.$24K
- Novartis$9K
- Amgen$6K
- Merck$4K
What the payments were for
- Consulting fees$2,92564%
- Food & beverage$1,56534%
- Education$521%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Karyopharm Therapeutics Inc. | 2 | $2,259 |
| AbbVie | 2 | $698 |
| Sanofi | 3 | $349 |
| Johnson & Johnson | 5 | $260 |
| Pfizer | 5 | $172 |
| E.r. Squibb & Sons, L.L.C. | 2 | $170 |
| AstraZeneca(2 entities) | 4 | $119 |
| Gilead | 1 | $116 |
| Menarini Silicon Biosystems, Inc. | 1 | $106 |
| Bristol Myers Squibb | 3 | $73 |
| GSK | 2 | $46 |
| Adaptive Biotechnologies Corporation | 1 | $29 |
| Tempus AI, Inc | 1 | $25 |
| Genentech USA, Inc. | 1 | $23 |
| Sanofi-aventis U.S. LLC | 1 | $23 |
| Merck | 1 | $22 |
| Cycle Pharmaceuticals Inc | 1 | $21 |
| Incyte Corporation | 1 | $17 |
| Janssen Scientific Affairs, LLC | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,542 in reported general payments places this provider in the 40th percentile of 65 hematology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 205 | $3,040,627 |
| PomalystPomalidomide | 77 | $1,657,056 |
| NinlaroIxazomib Citrate | 55 | $702,561 |
| CalquenceAcalabrutinib Maleate | 22 | $327,809 |
| EliquisApixaban | 28 | $18,662 |
| ValacyclovirValacyclovir Hcl | 251 | $12,926 |
| Imatinib Mesylate | 14 | $4,764 |
| Dexamethasone | 97 | $1,913 |
| Fentanyl | 19 | $1,384 |
| Hydroxyurea | 62 | $1,366 |
| Acyclovir | 62 | $737 |
| IpolPoliomyelitis Vaccine, Killed | 11 | $654 |
| Gabapentin | 65 | $614 |
| Potassium Chloride | 75 | $605 |
| Daptacel DtapDiph,pertuss(Acell),tet Ped/Pf | 22 | $543 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $73 | $3,040,627205 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $170 | $1,657,05677 claims |
| AstraZenecaCalquence | $119 | $327,80922 claims |
| PfizerEliquis | $172 | $18,66228 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 65 hematology providers in North Carolina.
Other hematology in Winston Salem
- Franklin ChenWinston Salem$307K
- James DuganWinston Salem$200K
- Kathleen ElliottWinston Salem$7K
- Konstantinos LontosWinston Salem$3K
- Ryan JacobsCharlotte$1.5M
- Alan Zausner SkarbnikCharlotte$1.1M
- Mohamed MohamedGreensboro$841K
- Raymond ThertulienCharlotte$561K
- Ruben MesaCharlotte$384K
- Michael GrunwaldCharlotte$344K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.